Replies to post #298 on Crispr Therapeutics AG (CRSP)

[Zeppo]

Good news seems to be on the long-term horizon. The problem is the time it takes to adequately test dosage. Ten patients isn't going to cut the mustard and get this product into Phase III for several years. I have seen this scenario happen with other companies. Stocks get ruined because the companies are more interested in trying to perfect dosage than to take a positive dosage and navigate it through advanced trials. APTOF is a prime example of that type of history.

[jondoeuk]

An update https://www.globenewswire.com/news-release/2025/06/26/3105698/0/en/CRISPR-Therapeutics-Reports-Positive-Additional-Phase-1-Data-for-CTX310-Targeting-ANGPTL3-and-Provides-Update-on-In-Vivo-Cardiovascular-Pipeline.html

''New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile

Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025

Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026

Preclinical in vivo cardiovascular program CTX340™ advancing toward IND / CTA filings targeting refractory hypertension.''